Introduction
GXCPC1 is an allogeneic adipose-derived stem cells (ADSCs) therapy for treating osteoarthritis (OA). GXCPC1 has demonstrated that it possesses great therapeutic potential for regenerating cartilage in pre-clinical data. Currently, GXCPC1 is ongoing in clinical trial phase I/II (NCT03943576).
Features / strengths
．Allogeneic stem cell therapy
．Do not need to wait (Off-the-shelf)
．Appropriate volume for joint space (3ml)
．The allogeneic cell bank is fully complied with the medical regulation
．The status of clinical trial is progressing ahead of others (Phase II follow-up finished)
Specification in detail
Material
Adipose-derived stem cells (ADSCs)
Indication
Knee osteoarthritis (OA)
Administration
Intra-articular injection
Product Status
Phase I/II (NCT03943576)
